Keyphrases
C-Abl
100%
Topoisomerase II
100%
Human Sources
100%
Homologous Recombination
100%
Commensal Escherichia Coli
100%
Homology-directed Repair
100%
Community Setting
100%
High Prevalence
100%
High-grade Serous Ovarian Cancer (HGSOC)
50%
Topoisomerase Inhibitors
50%
Homologous Recombination Proficient
50%
Mitoxantrone
50%
Combination Treatment
50%
Non-homologous End Joining
50%
LMIC
40%
Treatment-resistant
25%
Homologous Recombination Deficiency
25%
Critical DNA
25%
Targeted Chemotherapy
25%
DNA Repair Pathways
25%
DNA Repair
25%
Imatinib
25%
Ovarian Cancer Cells
25%
Patient-derived Cell Line
25%
Disease Course
25%
G2-M Arrest
25%
Cancer Development
25%
Cell Cycle Delay
25%
Double-strand Breaks
25%
Chemotherapy Resistance
25%
Treatment Resistance
25%
Repair Method
25%
Induced Stress
25%
Enhanced Sensitivity
25%
Resistant Bacteria
10%
Search Data
10%
Enteric Bacteria
10%
Main Reservoir
10%
Ampicillin
10%
Oxytetracycline
10%
Nalidixic Acid
10%
Cefepime
10%
Chloramphenicol
10%
Streptomycin
10%
Mobile Genetic Elements
10%
Prevalence Data
10%
Policy Design
10%
Acute Care Setting
10%
Global Health Crisis
10%
Hospital Clinic
10%
Medicine and Dentistry
Homologous Recombination
100%
Gene Targeting
100%
DNA Topoisomerase (ATP Hydrolysing)
100%
DNA Damage
50%
DNA Repair
33%
Non-Homologous End Joining
33%
Gyrase Inhibitor
33%
Malignant Neoplasm
33%
Ovarian Cancer
16%
Low Drug Dose
16%
Imatinib
16%
Ovarian Cancer Cell Line
16%
Cell Cycle
16%
Protein Tyrosine Kinase
16%
Programmed Cell Death
16%
Diseases
16%
Tumor Cell
16%
Cell Line
16%
Pharmacology, Toxicology and Pharmaceutical Science
Commensal Escherichia Coli
100%
Gyrase Inhibitor
66%
Imatinib
33%
Cefotaxime
10%
Tetracycline
10%
Enterobacteriaceae
10%
Cotrimoxazole
10%
Streptomycin
10%
Ciprofloxacin
10%
Nalidixic Acid
10%
Ampicillin
10%
